Skip to main content
. 2021 Mar 12;12(3):268. doi: 10.1038/s41419-020-03269-0

Fig. 3. WEHI-7326 reduces the growth of multiple tumor types in xenograft models.

Fig. 3

Tumor growth curves of tumor xenografts in Balb/c nude mice. a–c LIM2537 (colon carcinoma), U87MG(Δ2–7) (glioblastoma) or H1437 (non-small cell lung carcinoma) were implanted subcutaneously in female mice. Treatment with vehicle or WEHI-7326 was initiated at day 5 and administered three times weekly via intraperitoneal injection. Tumor diameters were measured thrice weekly and used to calculate tumor volume. Data show mean±SEM (n = 8). d LoVo (colon carcinoma) in male mice. Treatment with vehicle or WEHI-7326 (biweekly) was administered via tail vein injection. Tumor diameters were measured twice weekly and used to calculate tumor volume. Data show mean±SEM (n = 5). e PC3 (human prostate carcinoma) in male mice. Treatment with vehicle (saline), Docetaxel (weekly) or WEHI-7326 (biweekly) was administered via tail vein injection. Tumor diameters were measured twice weekly and used to calculate tumor volume. Vertical line in left graph show docetaxel treatment. Data show mean ± SEM (n = 10). f MDA-MB-231 LNA DRE (docetaxel resistant breast cancer) in female mice. Treatment with control vehicle, docetaxel (weekly) or WEHI-7326 (biweekly) was administered via tail vein injection. Tumor diameters were measured thrice weekly and used to calculate tumor volume. Vertical line in left graph show docetaxel treatment. Data show mean ± SEM (n = 12). Upward ticks on x-axis depict drug administration points for WEHI-7326, dotted blue lines for docetaxel. P-values for differences in tumor volume (compared to vehicle) were generated via unpaired t-tests; p > 0.05 (ns), p < 0.05 (*), p < 0.01 (**) and p < 0.0001 (****).